Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Despite a late start, the American firm is bearing down on its Danish rival
Eli
since
auto-detected in 361 stories
2 days ago
7 days ago
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy to help."
16 days ago
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
22 days ago
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Jim Cramer said Eli Lilly's new trial data has turned the obesity market into a 'one-horse race.'
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
35 days ago
Tariffs 'hard to come back from', says US pharma boss
Eli Lilly's boss tells the BBC he is doubtful tariffs will bring jobs to the US or raise billions in taxes.